95.17
BATS BZX Real-Time Price
As of 10:34am ET
 +1.28 / +1.36%
Today’s Change
88.32
Today|||52-Week Range
147.17
-8.81%
Year-to-Date
Merck to Buy Australian Firm to Boost Immunotherapy Pipeline
9:09am / Zacks.com - Paid Partner Content
FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
Feb 16 / Zacks.com - Paid Partner Content
What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?
Feb 20 / Zacks.com - Paid Partner Content
Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y
Feb 15 / Zacks.com - Paid Partner Content
David Rolfe Axes TreeHouse Foods, Exxon Mobil in 4th Quarter
Feb 19 / GuruFocus News - Paid Partner Content
Agios Pharmaceuticals (AGIO) Q4 Earnings: What's in Store?
Feb 09 / Zacks.com - Paid Partner Content
Celgene Reports Positive Data on Dermatology Drug Otezla
Feb 19 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close93.89
Today’s open94.37
Day’s range94.37 - 95.57
Volume76,444
Average volume (3 months)8,195,489
Market cap$70.6B
Data as of 10:34am ET, 02/22/2018

Growth & Valuation

Earnings growth (last year)+46.18%
Earnings growth (this year)+14.02%
Earnings growth (next 5 years)+18.50%
Revenue growth (last year)+17.40%
P/E ratio26.1
Price/Sales6.58
Price/Book10.30

Competitors

 Today’s
change
Today’s
% change
GSKGlaxoSmithKline+0.12+0.32%
BMYBristol-Myers Squibb-0.16-0.24%
NVONovo Nordisk+1.51+2.93%
ABBVAbbVie+1.19+1.01%
Data as of 10:34am ET, 02/22/2018

Financials

Next reporting dateApril 26, 2018
EPS forecast (this quarter)$1.95
Annual revenue (last year)$12.8B
Annual profit (last year)$2.9B
Net profit margin22.93%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Mark J. Alles
President &
Chief Operating Officer
Scott Andrew Smith
Corporate headquarters
Summit, New Jersey

Forecasts